RJA
PTCT icon

Raymond James & Associates’s PTC Therapeutics PTCT Stock Holding History

Raymond James & Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$342K Buy
+9,219
New +$309K ﹤0.01% 3334
2023
Q2 		– Sell
-5,183
Closed -$251K – 3945
2023
Q1 		$251K Sell
5,183
-2,849
-35% -$130K ﹤0.01% 3361
2022
Q4 		$307K Buy
8,032
+2,863
+55% +$119K ﹤0.01% 3201
2022
Q3 		$259K Buy
5,169
+13
+0.3% +$637 ﹤0.01% 3278
2022
Q2 		$207K Sell
5,156
-3,185
-38% -$112K ﹤0.01% 3495
2022
Q1 		$311K Buy
8,341
+1,243
+18% +$47.9K ﹤0.01% 3390
2021
Q4 		$283K Sell
7,098
-27
-0.4% -$1.03K ﹤0.01% 3474
2021
Q3 		$265K Buy
7,125
+311
+5% +$12.8K ﹤0.01% 3501
2021
Q2 		$288K Sell
6,814
-6,650
-49% -$285K ﹤0.01% 3463
2021
Q1 		$638K Buy
13,464
+3
+0% +$178 ﹤0.01% 2831
2020
Q4 		$822K Sell
13,461
-7,763
-37% -$458K ﹤0.01% 2465
2020
Q3 		$992K Buy
21,224
+940
+5% +$46.3K ﹤0.01% 2186
2020
Q2 		$1.03M Buy
20,284
+6,329
+45% +$311K ﹤0.01% 2145
2020
Q1 		$623K Buy
13,955
+6,887
+97% +$347K ﹤0.01% 2268
2019
Q4 		$339K Buy
7,068
+43
+0.6% +$1.83K ﹤0.01% 3008
2019
Q3 		$238K Sell
7,025
-4,197
-37% -$183K ﹤0.01% 3154
2019
Q2 		$505K Buy
11,222
+3,837
+52% +$152K ﹤0.01% 2657
2019
Q1 		$278K Hold
7,385
– – ﹤0.01% 3022
2018
Q4 		$253K Buy
+7,385
New +$266K ﹤0.01% 2970
2016
Q1 		– Sell
-54,660
Closed -$1.77M – 2960
2015
Q4 		$1.77M Sell
54,660
-10,212
-16% -$301K 0.01% 1336
2015
Q3 		$1.73M Buy
+64,872
New +$2.77M 0.01% 1299

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's PTCT Position: Q3 2024 in Review

Raymond James & Associates opened a new position in PTC Therapeutics (PTCT) in Q3 2024: 9,219 shares worth $342K. The stake represents ﹤0.01% of the portfolio and ranks #3334 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in PTCT as recently as Q1 2023.

Raymond James & Associates first reported a position in PTCT in Q3 2015 and has held it in 21 quarters since. The position peaked at $1.77M in Q4 2015. 202 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • Raymond James & Associates held 9,219 shares of PTC Therapeutics worth $342K as of Q3 2024.
  • PTC Therapeutics was a new Raymond James & Associates position in Q3 2024.
  • PTC Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3334 holding.
  • Raymond James & Associates first reported a position in PTC Therapeutics in Q3 2015 and has held it in 21 quarters since.
  • Raymond James & Associates's PTC Therapeutics position peaked at $1.77M in Q4 2015.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.